Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
Timothy Brighton(Prince of Wales Hospital), Hartmut Goldschmidt(Heidelberg University), Amit Khot(The Royal Melbourne Hospital), Mercedes Gironella(Vall d'Hebron Hospital Universitari), Britte Kranenburg(Janssen (Netherlands)), Sepideh Nemat(Janssen (United Kingdom)), Hila Magen(Sheba Medical Center), Albert Oriol(Institut Català d'Oncologia), Rajesh Bandekar(Springhouse), Matthew Streetly(King's College - North Carolina), Mary Guilfoyle(Janssen (United States)), David Ghez(Hôpital Necker-Enfants Malades), Ming Qi(Janssen (United States)), Peter Hu(Janssen (United States)), Simon J. Harrison(Peter MacCallum Cancer Centre), A. Kirsch(Stiftung Oskar Helene Heim), Xiang Qin(Changsha Medical University), Brendan M. Weiss(Heidelberg University)
Cited by 71
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719